INTRODUCTION {#S1}
============

Gliomas, including glioblastomas (GBs), are the most common and lethal primary adult brain tumors ([@R65], [@R66]; [@R97]). They are characterized and defined by their highly aggressive nature, involving rapid tumor growth, diffuse invasiveness, and resistance to therapy ([@R82]). GBs are made up of a heterogeneous population of tumor cells and various types of stromal cells, which all contribute to tumor progression and resistance to treatment ([@R9]; [@R30]; [@R69]). GB cells exert effects on endogenous CNS cell types, such as microglia, astrocytes, oligodendrocytes, endothelial cells, and neurons, as well as infiltrating monocytes and/or macrophages (MOs and/or macrophages) ([@R9]; [@R69]). Among these different cell types, microglia and MOs and/or macrophages are the most prevalent cell types within the tumor ([@R60], [@R61]). Microglia are the resident innate immune cells in the brain ([@R42]), whereas MOs residing in a tumor have infiltrated from the blood circulation and can subsequently differentiate to macrophages ([@R8]). In response to tumor stimuli, these non-tumorigenic cells produce chemokines and cytokines, including growth and angiogenic factors, immunosuppressive molecules, and extracellular matrix-modifying enzymes, which make the environs favorable to tumor progression ([@R30]; [@R43]).

In addition to soluble factors, GB cells communicate with surrounding cells by release of membrane-bound extracellular vesicles (EVs) containing proteins, lipids, and RNA ([@R53]). Different RNA species are found in their EVs, including microRNA (miRNA), small nucleolar RNA, Y RNA, mitochondrial RNA, and vault RNA, as well as long non-coding RNA and mRNA ([@R64]; [@R96]). EVs are known to carry specific RNA cargo from donor cells to recipient cells ([@R79]; [@R89]). Because the lipid bilayer of the EVs protects the cargo from degradation, EV contents can be delivered to closely surrounding cells as well as distant recipient cells. Increasing evidence suggests that content can be loaded selectively into EVs (e.g., RNA) ([@R55]) and, once transferred, affect the phenotype of recipient cells, as studied *in vitro* ([@R17]; [@R79]; [@R88]; [@R89]; [@R90]).

miRNAs are small RNAs, involved in the target cleavage, translational repression, and deadenylation of mRNA ([@R99]). Among them, miRNA-21 (miR-21) is the most studied in the context of cancer generally and in glioma specifically. The promoter and mature miRNA sequence for miR-21 is highly conserved across a number of vertebrate species ([@R39]), with the transcription of miR-21 regulated through an independent promoter site located in the intron region of a protein-coding gene ([@R26]). miR-21 has been shown to play a role in embryogenesis, self-renewal, and development in normal cell physiology, but its expression is dysregulated in the context of oncogenic processes ([@R40]; [@R68]). Furthermore, miR-21 expression is associated with cell differentiation and depending on the model system is shown to induce osteogenic differentiation and inhibit neural stem cell differentiation ([@R28]; [@R95]). In GB it has been shown that miR-21 acts as an important oncogene ([@R10]; [@R39]) as high levels of miR-21 in GB lead to the downregulation of the tumor suppressor gene IGFBP3 ([@R104]) and are associated with activation of metalloproteinases ([@R27]). The expression level of miR-21 is inversely correlated with the survival rate of GB patients ([@R104]). miR-21 has been identified as a cerebrospinal fluid (CSF) biomarker for monitoring glioma growth and therapy response ([@R85]). In addition, studies evaluating GB-derived EVs in CSF indicated that elevated miR-21 levels are associated with worse prognosis ([@R4]; [@R77]). Interference with miR-21 reduces the malignant potential, as downregulation of miR-21 has been shown to inhibit cell proliferation and invasion *in vitro* and tumor progression *in vivo* ([@R6]; [@R16]; [@R27]; [@R68]).

In this study we investigated the transfer of miRNA by glioma EVs between tumor and stromal cells using miR-21 as the model miRNA. Using a mouse glioma cell line, GL261, stably expressing a palmitoylated fluorescent protein, we monitored the uptake of EVs by microglia and MOs and/or macrophages in the brain ([@R41]; [@R90]). To avoid interference by endogenous recipient cell miR-21, GL261 cells were implanted in the brains of mice lacking expression of miR-21 ([@R52]). Using this reporter we were able to study the uptake of naturally shed EV in an *in vivo* setting. This approach avoids many of the technical issues hampering EV research, such as mechanical manipulation, subselecting for specific EV populations during isolation, and the injection or incubation with an arbitrary number of EVs ([@R1]; [@R86]).

Here we demonstrate functional delivery of miR-21 from glioma cells to the surrounding innate immune cells subsequently leading to downregulation of specific miR-21 mRNA targets. Additionally, injection experiments using isolated glioma-derived EVs confirm that the observed effects can be mediated by EVs, although we do not exclude additional involvement of other miR-21 carriers, such as large EV or non-floating non-EV components. Taken together this proves functional EV-mediated miRNA transfer *in vivo* using spontaneously released EVs resulting in reprogramming of microglia.

RESULTS {#S2}
=======

GL261-Derived EVs Contain High Levels of miR-21 {#S3}
-----------------------------------------------

To study the functional extracellular transfer of miRNAs from tumor to surrounding cells *in vivo*, we use syngeneic mouse glioma cells, GL261.palmGFP.H2B.mRFP (GL261.pGHR) ([Figure 1A](#F1){ref-type="fig"}). GL261 cells expressing a palmitoylated form of GFP facilitate tracking of the uptake of tumor-derived membrane fragments, including EVs, into stromal cells in the tumor microenvironment ([@R41]; [@R90]). In addition, the nuclear localized RFP fused to the H2B histone helps discriminate EV uptake from phagocytosis of whole cells ([@R98]). Using differential ultracentrifugation ([Figure 1B](#F1){ref-type="fig"}), larger vesicles and cell fragments pelleted at 2,000 × *g*, EVs, including exosomes and microvesicles, isolated from GL261 cell conditioned medium by centrifugation at 100,000 × *g*. Heterogeneity of these different fractions was confirmed by probing for different vesicular protein markers that are present in all types of EVs and larger vesicle fractions (Flotillin-1) ([@R38]), those typically associated with exosomes and absent in 2,000 × *g* (ALIX and TSG101), and GAPDH found to be enriched in the 2,000 × *g* and cellular fraction ([@R59]). Importantly, GFP protein was detected in both cellular and extracellular fractions, confirming that this marker can be used to track the fate of all different subtypes of EVs ([Figure 1C](#F1){ref-type="fig"}). Nanoparticle tracking analysis (NTA) of the EVs isolated by 100,000 × *g* ultracentrifugation revealed a broad size distribution of EVs ranging from 100 to 500 nm, further confirming their heterogeneity ([Figure S1A](#SD1){ref-type="supplementary-material"}). Importantly, miR-21 was present in GL261 cells, 2,000 × *g* fraction, and GL261-derived EVs, with significantly higher levels of miR-21 in the EVs compared with cellular levels ([Figures 1D](#F1){ref-type="fig"} and [1E](#F1){ref-type="fig"}). The level of miR-21 in cells, the 2,000 × *g* fraction, and EVs was higher than the level of to the miR-10b, a miRNA uniquely expressed in glioma ([@R21]), compared with normal brain ([Figures S1B](#SD1){ref-type="supplementary-material"} and [S1C](#SD1){ref-type="supplementary-material"}). To further confirm the presence of miR-21 in EVs, we separated the different-sized vesicles collected at 100,000 × *g* and performed an iodixanol gradient. The EVs were bottom-loaded, and the gradient was performed over 16 h at 156,000 × *g* ([Figure S2A](#SD1){ref-type="supplementary-material"}). In total, 12 fractions were collected and analyzed for GFP protein levels, as well as miR-21 levels. Overall, miR-21 was found to co-localize with GFP, but miR-21 was also present in the high-density fractions, possibly associated with high-density lipoproteins ([Figures S2B](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}) ([@R91]). Taken together, the heterogeneous population of EVs shed by tumor cells is labeled with membrane-bound GFP and contains high levels of miR-21.

Tumor-Derived EVs Effectively Deliver miR-21 to Microglia {#S4}
---------------------------------------------------------

Next, GL261.pGHR cells or carrier fluids were injected in adult miR-21-null mouse brains. By using miR-21-null mice, we were able to differentiate between endogenous upregulation of miRNAs following tumor implantation and the transfer of exogenous miR-21 from the tumor to stromal cells. In this model, endogenous miR-21 is not expressed in stromal cells, so the presence of miR-21 should be derived exclusively from the implanted tumor cells. Three weeks after implantation, mice were euthanized, and brains were mechanically and enzymatically digested for subsequent fluorescence-activated cell sorting (FACS) ([Figure 2A](#F2){ref-type="fig"}). Microglial cells were sorted on the basis of the absence of RFP (black gate) and levels of CD11b and CD45 (blue gate) ([@R7]). A carrier fluid-injected (mock) brain was used to determine the GFP cut-off (red and green gate) ([Figure 2B](#F2){ref-type="fig"}). From tumor-bearing brain, microglial cells were isolated with the control GFP cut-off used to separate cells negative for GFP (red box; EV-GFP^neg^) and positive for GFP (green box; EV-GFP^pos^). The presence of GFP in microglia thus indicates tumor-derived EV uptake ([Figure 2C](#F2){ref-type="fig"}). The expression level of miR-21 was detected at significantly higher levels in microglia, which had taken up tumor EVs compared with GFP-negative cells ([Figure 2D](#F2){ref-type="fig"}). The difference detected between mock microglia and EV-GFP^neg^ microglia could be due to uptake of high-density lipoproteins, which carry some miR-21 ([Figure S2](#SD1){ref-type="supplementary-material"}). A similar trend between EV-GFP^neg^ and EV-GFP^pos^ microglia was seen in glioma-specific miR-10b, in which the expression level was higher than in EV-GFP^neg^ microglia ([Figure S1D](#SD1){ref-type="supplementary-material"}). Using a similar approach, MOs and/or macrophages were identified by their high expression of CD45 and CD11b (blue gate, as indicated in the figure legend) ([@R7]), separating GFP-positive cells from GFP-negative cells ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). Similar to the microglial cells, an increased level of miR-21 was detected in EV-GFP^pos^ MOs and/or macrophages in comparison with EV-GFP^neg^ cells ([Figure 3C](#F3){ref-type="fig"}). Surprisingly the difference between EV-GFP^neg^ and GFP^pos^ in MOs and/or macrophages was smaller, and the relative levels in EV-GFP^pos^ MOs and/or macrophages were lower compared with EV-GFP^pos^ microglia ([Figures 2D](#F2){ref-type="fig"} and [3C](#F3){ref-type="fig"}). To further validate that the GFP uptake is caused by EV-sized particles rather than phagocytosis of complete cells, ImageStream analysis was used to visualize the uptake of GFP in microglial cells and MOs and/or macrophages (CD11b-PE, CD45-PE-Cy7 positive), using anti-GFP conjugated with Alexa Fluor 647 to exclude auto-fluorescence frequently encountered in myeloid cells and to confirm the uptake of GFP^pos^ vesicle-like structures ([Figures 2E](#F2){ref-type="fig"} and [3D](#F3){ref-type="fig"}). This analysis, as expected, did confirm the presence of subcellular GFP-positive particles in the microglial cells and MOs and/or macrophages cells ([Figures 2E](#F2){ref-type="fig"} and [3D](#F3){ref-type="fig"}). To confirm if the transfer of GFP is associated with functional miR-21 transfers into microglia, the miR-21 levels in cells after EV uptake were examined ([Figure 2D](#F2){ref-type="fig"}). To further investigate to what extend EVs are taken up by other immune cells, we quantified GFP uptake by CD11b^low^CD45^high^ lymphocytes ([Figure S3A](#SD1){ref-type="supplementary-material"}). In this population of non-phagocytic cells, we found a smaller percentage of cells that have taken up EV-GFP ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}). Moreover, the ImageStream and FACS analysis also allowed us to verify the expression of CD11b and CD45 on microglia and the absent of expression in tumor cells ([Figures S4A](#SD1){ref-type="supplementary-material"}--[S4D](#SD1){ref-type="supplementary-material"}). Taken together, this demonstrates that the combination of CD11b and CD45 can be used to isolate microglia and MOs and/or macrophages cells and that GFP-positive EVs released by tumor cells *in vivo* can transfer miR-21 to microglia.

EV-Mediated Transfer of miR-21 Leads to Downregulation of Specific mRNA Targets in Microglia {#S5}
--------------------------------------------------------------------------------------------

One of the main functions of miR-21 is mRNA target cleavage, leading to reduction of levels of specific mRNAs. To study this, we analyzed the mRNA transcriptome of microglia, which were separated by FACS on the basis of whether they contained EV-GFP. Unsupervised clustering of the top 750 most differentially expressed genes showed a clear distinction between microglia from control and tumor-bearing EV-GFP^neg^ and EV-GFP^pos^ microglia ([Figure 4A](#F4){ref-type="fig"}). To focus on the effect of the miR-21 transfer from tumor cells to microglia, the transcripts in EV-GFP^neg^ and EV-GFP^pos^ microglia were further analyzed. Four hundred forty-one genes were significantly upregulated and 359 genes were downregulated in EV-GFP^neg^ versus EV-GFP^pos^ ([Figure 4B](#F4){ref-type="fig"}, significantly changed genes in red). To further investigate miR-21 targets, we derived a list of miR-21 targets by merging the results from two publicly available databases (miRTarBase and miRWalk) ([@R13]; [@R19]; [@R20]); all references and evidence to miR-21 targets listed in the database were manually curated. To focus on validated targets rather than predicted targets, only genes from references showing direct downregulation of target genes on the basis of luciferase assays, qPCR analyses, or western blots were included ([Table S1](#SD1){ref-type="supplementary-material"}). Relative gene expression of the selected 59 target genes showed 25 genes with lowest expression in EV-GFP^pos^ microglia ([Figure 4C](#F4){ref-type="fig"}). The genes with significantly reduced expression in the EV-GFP^pos^ compared with EV-GFP^neg^ microglia (adjusted p \[p-adj\] \< 0.05) include *Nfat5, Bmpr2, Btg2, Rhob*, and *Kbtbd2* ([Figure 4C](#F4){ref-type="fig"}, significantly changed genes in bold). Interestingly, two genes (*FasL* and *Tgfbi*) regulated by miR-21 are expressed at a significantly higher level in EV-GFP^pos^ compared with EV-GFP^neg^ microglia (p-adj \< 0.05) ([Figure 4C](#F4){ref-type="fig"}). Overall, these results demonstrate that the transfer of miR-21 by EVs *in vivo* results in downregulation of some of the miR-21 target mRNAs.

miR-21 Downregulates Genes Involved in Cell Proliferation in Microglia {#S6}
----------------------------------------------------------------------

Although the selected mRNA targets ([Figure 4C](#F4){ref-type="fig"}), which are targets of miR-21 ([Table S1](#SD1){ref-type="supplementary-material"}), are found in a variety of cell types, we set out to validate these targets in microglia *in vitro.* Cultures of primary microglia isolated from neonatal miR-21-null mice were transfected with a miR-21 mimic and a scrambled control RNA. Subsequently, the levels of the mRNA targets identified in the *in vivo* setting were tested using qRT-PCR. From the selected genes, expression levels for *Btg2* and *Nfat5* as well as *Pdcd4* were significantly downregulated after EV uptake *in vivo* and were shown to be significantly downregulated by the miR-21 mimic ([Figure 5A](#F5){ref-type="fig"}). A control gene not targeted by miR-21, *Gapdh*, was not affected, an indication that mRNA target gene downregulation is miR-21 specific ([Figure 5B](#F5){ref-type="fig"}). In order to evaluate the effects of transfer of miR-21 by tumor-derived EVs to microglia in vitro, EVs from conditioned media (EV) and unconditioned media (UcM) (from cultures with and without GL261 cells, respectively) were isolated using a differential centrifugation protocol ([Figure 5C](#F5){ref-type="fig"}). Primary neonatal miR-21-null mouse microglia were then incubated with EVs and UcM. The microglia, 1 × 10^5^ cells, were exposed to a single dose of EVs, 2.43 × 10^10^ particles. Twenty-four hours later, the expression level of miR-21 was significantly increased in microglia exposed to GL261-derived EVs, compared with UcM ([Figure 5D](#F5){ref-type="fig"}). We also observed significant downregulation of the *in vivo* EV downregulated miR-21 targets *Bmpr2, Btg2, Kbtbd2, Pdcd4, Pten*, and *Rhob* transcripts, while *Gapdh* expression appeared unaffected ([Figures 5E](#F5){ref-type="fig"} and [5F](#F5){ref-type="fig"}). Also, we tested whether microglia from wild-type mice were also affected by the uptake of glioma-derived EV in a similar way. We exposed primary neonatal wild-type microglia to a single dose of EVs (2.43 × 10^10^ particles). Expression levels of the miR-21 targets were analyzed 24 h after EV exposure. Here we found similar trends of downregulation of the mRNA targets ([Figure S5A](#SD1){ref-type="supplementary-material"}). Using a similar approach as shown in [Figure 2](#F2){ref-type="fig"}, we isolated microglia from a tumor-bearing brain of a miR-21-expressing mouse and investigated the levels of miR-21 targets. We found similar patterns of downregulation of miR-21 targets in the miR-21 wild-type mice compared with miR-21-null mice ([Table S1](#SD1){ref-type="supplementary-material"}; [Figure S5B](#SD1){ref-type="supplementary-material"}). Taken together, these data demonstrate that miR-21, either introduced by transfection or delivered through EVs, can downregulate specific mRNAs in miR-21-null and wild-type microglia that were downregulated *in vitro* and *in vivo*.

Intracranial Delivery of GL261-Derived EVs Results in Effective Transfer of miR-21 in Endogenous Cells {#S7}
------------------------------------------------------------------------------------------------------

Our *in vitro* experiment showed that EV-mediated miR-21 transfer downregulates a select number of target mRNAs in microglia, hence it is important to evaluate whether this effect also occurs in an *in vivo* setting. By using EVs isolated from GL261, grown *in vitro*, we can study the uptake and effect of these EVs without confounding action of other factors released by the tumor cells. Using the previously described 100,000 × *g* EV isolation protocol ([Figure 1B](#F1){ref-type="fig"}), we resuspended the GL261-derived EVs in PBS. A total of 1.26 × 10^9^ particles as measured by NTA were used. A carrier control (PBS) was used to set the cut-off of the GFP within the microglial population (blue circle and green box) ([Figure 6A](#F6){ref-type="fig"}). Sixteen hours after injection of the EVs into the left striatum (using similar coordinates as tumor implantation) of miR-21-null mice, about 0.3% of all microglia in the brain (blue circle) that had taken up EVs (green box) were detected ([Figure 6B](#F6){ref-type="fig"}). Interestingly, miR-21 was detected in the EV-GFP^pos^ microglia, compared with being at non-detectable levels in EV-GFP^neg^ microglia, demonstrating that miR-21 was effectively transferred via EVs derived from *in vitro* cultured tumor cells and delivered to microglia *in vivo* ([Figure 6C](#F6){ref-type="fig"}). This EV uptake occurs soon after injection, as the EV-GFP signal was no longer detectable 40 h after injection of EVs (data not shown), indicating the degradation of EV-GFP. *In vitro* experiments showed that levels of *Pdcd4* and *Btg2* were regulated by miR-21 in microglia ([Figure 5A](#F5){ref-type="fig"}) and were shown to be down-regulated after exposure to glioma EVs ([Figure 5D](#F5){ref-type="fig"}). In this experiment, both transcript levels were reduced in microglia that took up EV-GFP, but this reduction reached significance only for the *Btg2* replicates ([Figure 6D](#F6){ref-type="fig"}). Interestingly, of the two targets, only *Btg2* was among the initially downregulated miR-21 targets *in vivo.* The levels of miR-21 were lower in the microglia after EV-GFP uptake (delivered intracranially), compared with the tumor samples or microglia transfected *in vitro.* The relatively low levels of miR-21 in the EV-GFP brain injection experiment may explain the incomplete downregulation of the *Pdcd4* gene. However, these results suggest that in the absence of a tumor, microglia can take up tumor cell-derived EVs injected into the striatum, leading to miR-21-dependent downregulation of *Btg2.*

Btg2 Downregulation Leads to Increased Microglia Proliferation {#S8}
--------------------------------------------------------------

A number of the downregulated genes, including *Pdcd4* and *Btg2*, are involved in cellular proliferation. Pathway analysis of genes differentially expressed at higher levels in EV-GFP^pos^ compared with EV-GFP^neg^ microglia indeed showed that a number of pathways involved in cell cycle control were upregulated, indicating a higher degree of proliferation in microglia after EV uptake ([Figure S6A](#SD1){ref-type="supplementary-material"}). To test whether microglia have a higher degree of proliferation after EV uptake, we analyzed the expression level of a number of genes that are described to be involved in microglial proliferation ([@R31]). All of these genes are expressed at higher levels in microglia from tumor-bearing brains, with the highest expression in EV-GFP^pos^ microglia ([Figure 7A](#F7){ref-type="fig"}). To further investigate the effect of miR-21 and *Btg2* on microglial proliferation, we transfected miR-21-knockout (KO) microglia with miR-21 mimic or small interfering RNA (siRNA) against *Btg2*. Thereafter, the number of Ki67-positive cells was quantified comparing miR-21 mimic versus scrambled control and siRNA targeting *Btg2* versus a siRNA control. Using a miR-21 mimic, a larger number of microglia express the Ki67 proliferation marker after 24 h of transfection ([Figures 7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}). The downregulation of *Btg2* after siRNA transfection also yielded a larger number of microglia expressing Ki67 ([Figures 7D](#F7){ref-type="fig"}--[7F](#F7){ref-type="fig"}). Overall, these results show that microglial proliferation is increased upon the delivery of miR-21 and after the downregulation of *Btg2*.

DISCUSSION {#S9}
==========

EV-mediated miRNA transfer downregulates specific mRNAs *in vivo*. By using a palmitoylated fluorescent protein stably expressed in tumor cells, we were able to track the uptake of tumor EVs by other cells in the brain ([@R41]; [@R90]). This reporter is not specific to one type of vesicles (e.g., exosomes, ectosomes, or microvesicles) ([@R14]) but follows the uptake of all naturally formed membrane-bound vesicles. Microglia are known to be highly infiltrative into gliomas, and we have shown that they avidly take up tumor-derived fluorescent EVs ([@R90]). Here we show that the cargo of the EVs is transferred into the microglia, resulting in the delivery of functional miR-21.

In the current literature, EVs isolated after ultracentrifugation (100,000 × *g* pellet) or smaller EVs isolated after size exclusion chromatography have been studied the most. We included the 2,000 × *g* pellet (composed mostly of apoptotic bodies) in our analysis as well, and even though we were able to detect miR-21 in these particles, we could not detect upregulation of miR-21 compared with cellular levels, as were found for the 100,000 × *g* pellet. Additionally by injecting the 2,000 × *g* pellet into non-tumor-bearing mice, we detected only incidental GFP uptake by microglia, indicating that the EVs isolated after ultracentrifugation are taken up to a greater extent microglial cells *in vivo.* Moreover, we found that miR-21 is also present in the high-density fractions by density gradient centrifugation (containing high-density lipoproteins), indicating that these may add to the EV-mediated miR-21 transfer and could explain the presence of miR-21 in GFP^neg^ microglia ([@R91]). Overall, the cargo of the glioma-derived EV subtypes is transferred into the microglia, resulting in the delivery of functional miR-21. Although EV-mediated miRNA transfer was previously either shown *in vitro* or after injection of arbitrary amounts of highly subselected EVs *in vivo*, this study demonstrates *in vivo* functional transfer of miRNA by spontaneously released EVs.

Because of their high abundance in tumor tissue, we focused in this study on the microglia and infiltrating MOs and/or macrophages. Analysis of the EV-GFP uptake and the subsequent miR-21 levels in miR-21-null mice showed that although the percentage of cells positive for EV-GFP uptake was highest in the MO and/or macrophage population, the miR-21 transfer was most efficient in microglia. This could be due to differential uptake mechanisms; for example, microglia have been known to take up EV through macropinocytosis, whereas MOs and/or macrophages use phagocytosis, possibly followed by degradation ([@R25]). These differential uptake mechanisms can result in the difference of miR-21 level detected. So far, it has been reported that EVs derived from oligodendrocytes, glioma cells, and neural stem cells are taken up by microglia ([@R25]; [@R62]; [@R90]). Within the developing brain, the role of EVs in the communication between neural stem cells and neighboring microglia has also been shown to change the transcriptional state of the latter ([@R62]). Here, we used flow cytometry and image flow cytometry to visualize the uptake of fluorescently labeled EVs by microglia. By analyzing the transcriptome of the tumor-associated miR-21-null microglia, we observed downregulation of miR-21 target mRNAs after uptake of tumor EVs. Overall, following uptake of the fluorescent EVs, miR-21 needs to exit the vesicles to become functional. Upon release of miR-21 and palmitoylated GFP (palmGFP) into the cytosol, the palmGFP might associate with other membranes in the cells and would probably be diluted out so as to be lost visually. Alternatively, a fraction of miR-21 and palmGFP might be retained in endosomes and degraded in late endosomes and lysosomes. Because the uptake of palmGFP EVs is most probably not a one-time but a continuous process, palmGFP and thus levels of miR-21 in cells may be in both the endosomes and cytosol and/or membranes. The downregulation of target mRNAs as we detected supports the notion that miR-21 is release into the cytosol after uptake of miR-21^+^ tumor EVs. Although other EV components, such as different small and large RNAs as well as proteins and lipids, are also anticipated to affect microglia, we have, by making use of the miR-21-null mouse, been able to dissect the effects of the transfer of this single miRNA. Especially for *Btg2* we were able to show EV miR-21-mediated knockdown *in vivo* and were able to validate the role of EVs in additional *in vivo* and *in vitro* studies.

Here, we have demonstrated a mechanism through which a tumor can change the molecular profiles of microglia. EV-mediated transfer of miRNA from tumor cells to microglia results in downregulation of specific target genes. The gene that was most strikingly altered by EV-mediated miR-21 transfer was *Btg2* (synonyms, *Pc3* and *Tis21*). This gene belongs to the BTG/Tob protein family, which is composed of six genes (*BTG1, BTG2/PC3/Tis21*, *BTG3/ANA, BTG4/PC3B, Tob1/Tob*, and *Tob2*), and all are involved in the control of cellular proliferation and differentiation ([@R56]). *Btg2* negatively controls proliferation by reducing the activity of cyclin D1, which drives the cell cycle, as shown in medulloblastoma cells ([@R22]), and by inhibiting cell cycle transition from G1 to S phase in fibroblasts ([@R29]). Increased levels of proliferation in microglia have been reported in neuro-inflammation and traumatic brain injury, indicating that disruption of CNS homeostasis as is also occurring during tumor growth can result in proliferation of microglia ([@R23]; [@R67]). By downregulation of *Btg2* through transfection with miR-21 mimic or siRNA specific to this message, we showed an increased level of proliferation in microglia in culture. Within a tumor it is possible that by reducing the antiproliferative effects of *Btg2* in tumor-supporting microglia, these cells will increase proliferation, resulting in an increased influence on shaping the tumor microenvironment. In addition, it has also been shown that glioma cells exchange extracellular material, suggesting that EV-mediated miR-21 transfer can also increase glioma cell proliferation ([@R5]; [@R79]).

In conclusion, the results of this study demonstrate that glioma cells can reprogram microglia in part by transferring miR-21 through EVs. Using the fluorescent palmitoylated EV reporter, we have been able to study the uptake of naturally secreted EVs *in vivo.* Reviewing our data, we propose a model in which EVs secreted by tumor cells function as miRNA carriers, which deliver molecules that change the transcriptome and subsequent proliferative capacities of microglia. This observation opens up new opportunities for therapy aimed at disrupting this form of communication between tumor cells and surrounding cells, including tumor-associated microglia. It is proof that miRNAs can be transferred by EVs to cells in the brain *in vivo* with functional consequences.

STAR★METHODS {#S10}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S11}
---------------------------------------

This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Xandra O. Breakefield (<breakefield@hms.harvard.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Animals {#S13}

All animal experiments were conducted under the oversight of the Massachusetts General Hospital Institution Animal Care and Use Committee. B6;129S6-MiR-21atm1Yoli/J (miR-21 null) mice were maintained with unlimited access to water and food under a 12-hour light/dark cycle ([@R52]). Male and female mice ranging from 12 -- 14 weeks in age were randomly assigned to experimental groups. For RNA sequencing 3 mice were assigned per group. Injection of EVs was also done with 3 animals per group.

### CELL CULTURE {#S14}

Mouse glioma cell-line GL261 (NCI Tumor Repository) was cultured at 37°C in a 5% CO~2~ humidified incubator. Culture media was comprised of Roswell Park Memorial Institute (RPMI) 1640 with L-glutamine (Corning) supplemented with penicillin (100 units/ml), streptomycin (100 mg/ml) (P/S) (Corning) and 10% fetal bovine serum (FBS) (Gemini Bioproducts). Cells were tested for mycoplasma contamination (Mycoplasma PCR Detection Kit, abm G238) and found negative. Cells grown for EV isolation were cultured in media supplemented with 5% EV-depleted FBS. FBS was depleted from EVs by 16 hours of ultracentrifugation at 160,000×g.

### PRIMARY MICROGLIA CULTURE {#S15}

Mixed glial cultures were isolated from cerebral cortices of P1 to P4 mouse pups. Meninges were removed, and cortical cells were dissociated using 0.05% Trypsin/EDTA (Corning) followed by cell straining using 100 μm and 40 μm cell strainers. Cells were cultured in DMEM with 20% FBS, 1% P/S and 10 ng/ml M-CSF (GIBCO) in poly-D-lysine (PDL; Sigma-Aldrich; 10 μg/ml) on pre-coated T-75 culture flasks for 10--15 days. Primary microglia were harvested from confluent mixed glial culture by gentle shaking on an orbital shaker for 30--60 min at 180 rpm and cultured in the same medium ([@R84]).

METHOD DETAILS {#S16}
--------------

### Lentiviral Transduction Reporter {#S17}

GL261 cells were stably transduced using a CSCW2 lentiviral vector ([@R75]) encoding palmitoylated GFP (palmGFP), resulting in membrane localized GFP expression in cells and EVs released by these cells ([@R41]; [@R57]). A second transduction was performed to stably express the H2B.mRFP reporter (Addgene \#18982, acquired from Dr. Thorsten Mempel, MGH) ([@R98]). Following transduction, cells were sorted for single cell cloning on the expression of both GFP and RFP. A clone with stable expression of both reporters was used for all experiments. For imaging of the cells, they were seeded on PDL (Sigma-Aldrich) coated glass coverslips and incubated for 48 hours. Cells were then washed in PBS and fixed using 4% paraformaldehyde (PFA; Electron Microscopy Sciences) in PBS. DAPI (1 μg/ml) (Thermo Fisher) staining was performed for 30 min at room temperature. Slides were washed for 10 min using PBS and mounted on microscopy slides using ProLong® Diamond Antifade Mountant (Thermo Fisher). Fluorescence microscopy images were acquired on the Zeiss Axio Imager M2 (Carl Zeiss).

### Proliferation assay {#S18}

miR-21 null primary microglia were seeded at the density of 70,000 cells/well on coverslips coated with poly-D-lysine (PDL; Sigma-Aldrich; 10 μg/ml). Microglia were transfected using DharmaFECT (Dharmacon) transfection reagent in Opti-MEM (GIBCO). miR-21 mimic and scrambled control were used at a concentration of 20 μM, siRNA against *Btg2* and siRNA control at 5 μM. Transfection mixes were incubated for 30 min before adding to the cells, which were subsequently incubated for 24 hours at 37°C. After incubation, microglia were washed in PBS for 5 min and fixed in 100% ice-cold methanol for 10 min. After fixation cells were washed two times in PBS for 5 min. Microglia were blocked in 5% BSA and 0.1% Triton X-100 (USB) in PBS (PBS-T) for 4 hours. Microglia were then incubated with the primary antibody Ki67 anti-rabbit (Abcam, 1:4000) at 4°C overnight. Microglia were washed three times in PBS-T for 5 min. Secondary antibody goat anti-rabbit (Invitrogen, 1:400) was diluted in PBS-T and incubated for 1 hour in dark at RT. Microglia were stained for DAPI (Thermo Fisher, 1 μg/ml) diluted in PBST and incubated for 5 min. Coverslips were transferred to microscope slides (Fisherbrand) on a droplet of mounting medium (Vectashield, Vector Labs). Fluorescence microscopy images were acquired on the Zeiss Axio Imager M2 (Carl Zeiss). Quantification of proliferation 24 hours was measured as Ki67 positive cells per total number of DAPI positive cells using ImageJ.

### Vesicle Isolation Including Iodixanol Density Gradient {#S19}

The differential ultracentrifugation protocol consisted of subsequent centrifugation at 300×g for 10 min and 2000×g 10 min. Two-thousand ×g pellet was collected and resuspended in PBS or RIPA buffer respectively for injection or western blot analysis. Supernatants were filtered through 0.8μm filter (Sigma) and centrifuged for 100,000×g (*k*-factor of 220.1) 120 min in Quick-Seal® Polypropylene Tubes (Beckman) using Type 70 Ti in Optima XE ultracentrifuge (Beckman) to pellet EVs. For EV exposure experiments and western blot analysis, pellets were resuspended in remaining supernatant supplemented with OptiMEM and concentrated by centrifugation at 100,000×g (*k*-factor of 190.7) for 120 min in Thinwall Polypropylene Tubes (Beckman) using MLS-50 Swinging-Bucket Rotor (Beckman) in an Optima Max-XP Ultracentrifuge. Final EV pellet was resuspended in DPBS for exposure experiment or RIPA buffer for western blot analysis.

Prior to western blot analysis cells and EVs were lysed in RIPA buffer with protease inhibitors (Sigma). Protein concentration was determined using Pierce BCA protein assay (Thermo Fisher) and equal amounts were loaded and resolved on 10% SDS-PAGE gel (Thermo Fisher). After transfer onto nitrocellulose membranes, samples were probed for GFP (Thermo Fisher, A-11120, 1:1000), GAPDH (Millipore, CB1001, 1:1000), TSG101 (Abcam, ab125011, 1:500), ALIX (Santa Cruz, sc-53538, 1:200) and Flotillin-1 (Abcam, ab133497, 1:500). ECL Anti-Rabbit IgG (Sigma) and ECL Anti-mouse IgG (Thermo Fisher) corresponding to the primary antibody were used as a secondary antibody.

For iodixanol density gradient the 100,000×g EV pellet was resuspended in 300 μl supernatant and mixed by adding 1 mL 60% cold iodixanol (OptiPrep Density Gradient Medium, Sigma D1556), the mixture was subsequently transferred to a Thinwall Polypropylene Tubes (Beckman). One layer of 500 μl of 40% and 30% iodixanol (diluted with 10× PBS and Milli-Q) were loaded on top of the 46% layer consisting EVs in the suspension of 60% iodixanol. The remaining volume was filled using 10% iodixanol. The density step-gradients were centrifuged at 156,000×g for 16 hours at 4°C in using an Optima Max-XP Ultracentrifuge. After 1 mL of the top layer was removed and 12 fractions of 250 μl were collected sequentially and numbered 1--12 from top to bottom. The different fractions were weighted determine density and used for western blot analysis and miRNA quantification.

For western blot analysis, 30 μl of each fraction was lysed in RIPA buffer with protease inhibitors (Sigma Aldrich). Protein concentrations were determined using Pierce BCA protein assay (Thermo Fisher) and equal amounts were loaded and resolved on 10% SDS-PAGE gel (Thermo Fisher). After transfer onto nitrocellulose membranes, samples were probed for GFP (Thermo Fisher, A-11122, 1:1000). ECL Anti-Rabbit IgG (Sigma) was used as secondary antibody corresponding to the primary antibody. The remaining volumes were used for RNA isolation and miRNA RT-qPCR quantification.

### Intracranial Tumor Injection {#S20}

Adult miR-21 null mice were first anesthetized using 2.5% isoflurane in 100% oxygen via a nose cone. The left striatum was then either injected with 1 × 10^5^ cells of GL261.palmGFP.H2B.mRFP (GL261.pGHR) suspended in 2 μL OptiMEM or OptiMEM alone. Using a stereotactic frame, the cells were implanted at three coordinates from bregma: 0.5 mm left, 2 mm anterior and a depth of 2.5 mm from the skull. Three weeks after implantation, the mice were anesthetized with 120 μL of a mixture of ketamine (17.5 mg/ml) and xylazine (2.5 mg/ml) followed by transcardial perfusion with 50 mL cold Dulbecco's phosphate-buffered saline (DPBS) without magnesium and calcium for subsequent FACS using a perfusion pump (Minipump Variable Flow, Fisher Scientific).

### Tissue Digestion {#S21}

Neural Tissue Dissociation Kit (P) (Miltenyi Biotec) was used to process the brain into a single cell suspension. Brains were placed into a GentleMacs C-tube (Miltenyi Biotec) with 1.9 mL Buffer X with 50 μl Neural Buffer P. Brain was dissociated using the gentleMACS Dissociator (Miltenyi Biotec) on the brain program settings, according to manufacturer's protocol. Myelin removal was achieved using magnetic separation together with anti-myelin beads (Miltenyi Biotec). The final cell suspension was re-suspended in 1X DPBS without calcium (Ca^2+^) or magnesium (Mg^2+^) (Corning) supplemented with 2 mM EDTA (Thermo Fisher) and 0.5% BSA (Sigma) following cell staining and FACS.

### Flow Cytometry Preparation {#S22}

Non-specific binding of the immunoglobulin to the Fc receptors was blocked by incubating cells 10 min on ice in 0.5% BSA in DPBS (without Ca^2+^ or Mg^2+^) with 2 mM EDTA supplemented with TruStain fcX (anti-mouse Cd16/32, BioLegend, \#101319, clone 93, 1:100). Cells were stained with anti-CD11B-Alexa647 (clone M1/70, 1:100) and anti-CD45-PE-Cy7 (clone 30-F11, 1:100) for 30 min on ice. Finally, cells were washed with 1 mL DPBS (without Ca^2+^ or Mg^2+^) with 0.5% BSA and 2 mM EDTA and were centrifuged at 300 × g for 10 min, resuspended in 0.5% BSA, 2 mM EDTA in DPBS (without Ca^2+^ or Mg^2+^) and passed through a 35 mm nylon mesh strainer (BD Falcon). DAPI was added to cells at final concentration of 1 μg/ml. Live cells were sorted using a BD FACSAria II SORP Cell Sorter. Sorted cells were directly lysed in RLT Plus buffer (QIAGEN) and RNA was extracted using the RNeasy Plus RNA isolation kit (QIAGEN) according to manufactures protocol following appendix D.

### Image Stream Analysis {#S23}

Following protocol described above to dissociate cells from the whole brain, cells were stained as listed above with anti-CD11B-PE (clone M1/70, 1:100) and anti-CD45-PE-Cy7. After staining, cells were fixed and permeabilized with BD Cytofix/Cytoperm following manufacturing protocol. After fixation and permeabilization cells were stained with anti-GFP-Alexa Fluor 647 (clone FM264G, 1:100) and DAPI to a final concentration of 1 μg/ml. Flow imaging was done using Amnis ImageStream mkII Imaging Flow Cytometer.

### Intracranial Injection of EVs {#S24}

Isolation of EV was done from conditioned media after 48 hours of culturing GL261 in RPMI with 1% P/S and 5% EV-depleted FBS (see "[Cell Culture](#S17){ref-type="sec"}"). The differential ultracentrifugation protocol consisted of subsequent centrifugation at 300×g for 10 min and 2000×g 10 min. Supernatants were filtered through 0.8μm filter (Sigma) and centrifuged for 100,000×g (*k*-factor of 220.1) 120 min in Quick-Seal® Polypropylene Tubes (Beckman) using Type 70 Ti in Optima XE ultracentrifuge (Beckman) to pellet EVs. To wash and concentrate EVs, pellets were resuspended in remaining supernatant supplemented with OptiMEM and concentrated by centrifugation at 100,000×g (*k*-factor of 190.7) for 120 min in Thinwall Polypropylene Tubes (Beckman) using MLS-50 Swinging-Bucket Rotor (Beckman) in an Optima Max-XP Ultracentrifuge. Final EV pellet was resuspended in DPBS and characterization of EVs was performed by size distribution analysis using nanoparticle-tracking analysis (NTA 3.2; Malvern), with screen gain set at 3.0 and camera level at 13.0.

Following procedures as described in intracranial tumor implantation method section EVs or an equal volume of carrier fluid (PBS) was injected intracranially. Microglia were isolated 16 and 40 hours after injection of EVs or DPBS following procedures, as previously described.

### RT-qPCR {#S25}

cDNAs for gene expression analysis with RT-qPCR were prepared using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). qPCR mix was prepared following manufacturing protocol of Power SYBR Green PCR Master Mix (Applied Biosystems). qPCR was performed using the QuantStudio 3 PCR system (Applied Biosystems). The cycling conditions used were 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min following dissociation analysis. All qPCR reactions were done in triplicate and normalized to *β-Actin* mRNA levels.

miRNA expression analysis was performed using miRCURY LNA miRNA PCR kit following manufacturing's protocol. miRNA expression was normalized to *U6* or UniSP6 spike-in RNA as listed in figure legends.

### Digital Droplet PCR (ddPCR) {#S26}

To evaluate gene expression of from cells isolated after intracranial injection of EVs, cDNA was prepared using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). Gene expression was analyzed using ddPCR following PrimePCR ddPCR Gene Expression Probe Assay. Using protocol as listed by manufacturer droplets were generated with DG8 Cartridge using QX200 droplet generator (Bio-Rad) and PCR performed with thermal cycling conditions as described. QX200 Droplet Reader and QuantaSoft Software (Bio-Rad) were used to analyze the gene expression.

### RNA Sequencing {#S27}

The RNA concentration and integrity (RIN score) were determined using the Agilent 2100 Bioanalyzer Pico-chips (Agilent Technologies) following manufacturing protocol. RNA libraries were prepared with poly(A) selection using 3′-SMART CDS Primer II A within the SMARTer Ultra Low Input RNA Kit for Sequencing--v3 (Clontech Takara) following manufacturer's protocol including ERCC RNA Spike-In Mix (Life Technologies). Following first strand synthesis, cDNA was purified with 1× Agencourt AMPure XP beads (Beckman Coulter), as described in SMARTer protocol. Nextera® XT DNA Library Preparation kit (Illumina) was used for sample barcoding and fragmentation according to the manufacturer's protocol. Library amplification and library barcoding were achieved within 12 cycles of PCR. Subsequent PCR products were purified with 1.8× Agencourt AMPure XP beads according Nextera XT protocol. Library quantification was done using the SYBR® FAST Universal qPCR Kit (KAPA Biosystems). Equal molar individual libraries were pooled, and the pool concentration was determined using the KAPA SYBR® FAST Universal qPCR Kit. Finally, libraries were diluted and denatured with the addition of 1% PhiX Sequencing Control V3 (Illumina). 75-bp paired-end reads were generated using NextSeq 500/550 High Output v2 kit (150 cycles) on an Illumina NextSeq (Illumina).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S28}
---------------------------------------

### Data Processing and Analysis {#S29}

Raw sequencing data were processed by aligning to the mm10 genome using the STAR v2.4.0h aligner, and removing duplicate using the MarkDuplicates (picard-tools-1.8.4). Read counts were generated with Gencode'sGRCm38.p3 GTF annotations as reference using htseq-count.

After aligning and read counting, the downstream analysis was performed using the DESeq2 (version 1.10) ([@R48]) in R (version 3.2.3). Differential expression analysis as performed in DESeq2 was subjected to statistical significance using Benjamini and Hochberg multiple testing adjusted p values. The regularized logarithm (rlog) values were used for unsupervised clustering of top 750 most differential expressed genes between samples and to plot heatmaps using the gplots (version 2.17) heatmap.2 function in R.

Pathway analysis was performed in MetaCore using differential expression values between EV-GFP^pos^ versus EV-GFP^neg^ as generated in DESeq2. A cut-off value of significance of multiple testing adjusted p value \< 0.05 was used to include differentially expressed genes.

Bar graph and MA plots were generated in GraphPad Prism (version 7.0c). Error bars display mean ± standard error of the mean (SEM). Significance was calculated using unpaired t test, multiple t tests and One-way ANOVA with Tukey's multiple comparisons test, with statistical significance defined as p \< 0.05.
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![miR-21 Is Abundantly Present in GL261 Tumor Cells and Isolated EVs\
(A) GL261 cells were transduced to stably express palmitoylated GFP (palmGFP; lower left panel) as a membrane marker and the H2B.mRFP (upper right panel) as a nuclear marker that co-localized with DAPI (lower right panel). Scale bar, 50 μm.\
(B) Schematic overview of EV isolation using differential centrifugation. Pellets acquired after first round of ultracentrifugation were concentrated by second round of ultracentrifugation to obtain purer population of EVs.\
(C) Western blot demonstrates vesicle markers (ALIX and Flotillin-1) excluding TSG101, enriched in EV lysates. GFP was detected in all lysates (equal protein amount loaded).\
(D) Expression level of miR-21 analyzed using qRT-PCR, as plotted in Ct value normalized to spike-in (UniSp6), shows similar levels of miR-21 in cells and 2000 × *g* fraction.\
(E) Expression level of miR-21 analyzed using qRT-PCR, as plotted in Ct value normalized to spike-in (UniSp6), shows higher levels of miR-21 in EVs compared with cells.\
Data represent three independent experiments and are presented as the mean with SEM (error bars). p \< 0.05, unpaired t test.](nihms-1052475-f0001){#F1}

![miR-21 Is Transferred to Microglia after Uptake of Tumor-Derived EVs\
(A) Schematic illustration of experimental setup using C57BL/6.miR-21-null mice implanted with GL261.palmGFP.H2B.mRFP glioma cells that release palmGFP fluorescent EVs. Brains were harvested 21 days after implantation. Tissue was dissociated using enzymatic and mechanic digestion and microglia sorted on the basis of cell markers and EV-GFP uptake.\
(B) Representative FACS plots showing gating strategy in which RFP expression is used to exclude tumor cells in downstream analysis, and subsequently microglia were identified as CD11b^high^/CD45^med^ cells (blue gate). Microglia were then sorted on the basis of the GFP signal, detected as the upper limit in control (no tumor).\
(C) In mice implanted with GL261.palmGFP.H2B.mRFP, similar analysis (as in B) revealed a population of GFP-positive microglia (green gate in the microglia plot).\
(D) Uptake of EV-GFP results in the elevated levels of miR-21 in microglia, compared with control microglia (blue), with Ct \> 40 considered baseline.\
(E) EV-GFP uptake visualized by imaging flow cytometry using ImageStream. Five representative cells presented showing EV-GFP co-localized with anti-GFP Alexa Fluor 647 within the contours of microglia as show by membrane marker CD11B and CD45. Scale bar, 10 μm.\
Data represent four independent experiments and are presented as the mean with SEM (error bars). \*p \< 0.05 and \*\*p \< 0.01, one-way ANOVA with Tukey's multiple-comparisons test.](nihms-1052475-f0002){#F2}

![miR-21 Is Transferred to Monocytes and/or Macrophages after Uptake of Tumor-Derived EVs\
(A) Monocytes and/or macrophages (MOs and/or macrophages) from miR-21-null mice were identified by FACS as CD11b^high^/CD45^high^ cells (magenta gate). MOs and/or macrophages were then sorted on the basis of the GFP signal detected as the upper limit in control (no tumor).\
(B) In mice implanted with GL261.palmGFP.H2B.mRFP, a population of GFP-positive MOs and/or macrophages was identified (green gate in the GFP/RFP plot).\
(C) Uptake of EV-GFP resulted in the presence of miR-21 in MOs and/or macrophages.\
(D) EV-GFP uptake was visualized by imaging flow cytometry using ImageStream. Scale bar, 10 μm.\
Data represent three independent experiments and are presented as the mean with SEM (error bars). One-way ANOVA with Tukey's multiple-comparisons test.](nihms-1052475-f0003){#F3}

![miR-21 Downregulates Target mRNAs in Tumor-Associated Microglia\
(A) In unsupervised clustering analysis, the top 750 most differentially expressed genes microglia clustered on the basis of tumor status and EV-GFP uptake status.\
(B) MA-plot shows 441 significantly upregulated and 359 downregulated genes (plotted in red) when comparing EV-GFP^pos^ with EV-GFP^neg^ microglia.\
(C) Heatmap shows relative gene expression for 59 validated miR-21 gene targets. Bold gene names indicate genes with p-adj \< 0.05 in differential expression analysis EV-GFP^pos^ versus EV-GFP^neg^ microglia.](nihms-1052475-f0004){#F4}

![miR-21 Regulates Selected Target Genes *In Vitro* in Primary Neonatal Microglia\
(A) In comparison with scrambled control, transfection of miR-21-mimic in primary neonatal miR-21-null mice microglia results in significant downregulation of miR-21 target genes (*Btg2, Nfat5*, and *Pcdc4*) normalized to *β-Actin.*\
(B) Transfection of miR-21-mimic in primary neonatal miR-21-null mice microglia did not affect a control gene *Gaphd* (not targeted by miR-21).\
(C) Schematic overview of EV isolation using differential centrifugation. EVs from conditioned media cultured with GL261 cells (EV) and unconditioned media (UcM) were subjected to differential centrifugation. Collected EV pellet was resuspended in PBS and added to miR-21-null microglia.\
(D) EVs from conditioned media (EV) and unconditioned media (UcM) were isolated and added to miR-21-null primary microglia followed by 24 h incubation. Increased levels of miR-21 were detected in microglia exposed to GL261-derived EV, compared with control media, with Ct \> 40 considered baseline.\
(E and F) Fold expression of miR-21 target genes (*Bmpr2, Btg2, Kbtbd2, Nfat5, Pdcd4, Pten, Rhob, Smad7*, and *Ski*) (E) and (F) *Gapdh*, a gene not targeted by miR-21, normalized to *β-Actin* in miR-21-null microglia exposed to GL261-derived EVs, compared with UcM.\
Data represent three independent experiments and are presented as the mean with SEM (error bars). \*\*p \< 0.01 and \*\*\*p \< 0.001, unpaired t test and multiple t test.](nihms-1052475-f0005){#F5}

![EV-GFP Uptake after EV Intracranial Injection\
(A and B) PBS (A) or GL261.palmGFP.H2B.mRFP (B) EVs were injected intracranially. After 16 h brains were dissociated and microglia were sorted on the basis of EV-GFP uptake.\
(C) Uptake of EV-GFP resulted in elevated levels of miR-21 in microglia; levels in EV-GFP^neg^ microglia were not detectable (n.d.), with Ct \> 40 considered baseline.\
(D) Gene expression analyzed using ddPCR showing that *Pdcd4* and *Btg2* expression is reduced after EV-GFP uptake.\
Data represent three independent experiments and are presented as the mean with SEM (error bars). \*p \< 0.05, multiple t test.](nihms-1052475-f0006){#F6}

![*Btg2* Downregulation Leads to Increased Microglia Proliferation\
(A) Normalized read count of genes involved in microglia proliferation ([@R31]).\
(B) Representative images of *in vitro* culture miR-21-null microglia transfected with miR-21 mimic and control showing DAPI and Ki67 staining 24 h after transfection. Scale bar, 100 μm.\
(C) Quantification of proliferation 24 h after transfection with miR-21 mimic or control as measured by Ki67-positive cells per total number of DAPI-positive cells.\
(D) Representative images of *in vitro* culture miR-21-null microglia transfected with siRNA against *Btg2* and siRNA control showing DAPI and Ki67 staining 24 h after transfection. Scale bar, 100 μm.\
(E) Quantification of proliferation 24 h after transfection with siRNA against *Btg2* or control as measured by Ki67-positive cells per total number of DAPI-positive cells.\
Data represent three independent experiments and are presented as the mean with SEM (error bars). \*\*\*p \< 0.001, multiple testing adjusted p value differential expression in (A), and \*\*\*p \< 0.001, unpaired t test in (C), (E), and (F).](nihms-1052475-f0007){#F7}

###### 

KEY RESOURCES TABLE

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  REAGENT or RESOURCE                                                              SOURCE                         IDENTIFIER
  -------------------------------------------------------------------------------- ------------------------------ -----------------------------------------------------------------------------
                                                                                                                  

  Antibodies                                                                                                      

                                                                                                                  

  Rabbit monoclonal TSG101                                                         Abcam                          Cat\# ab125011 RRID:AB_10974262

  Mouse monoclonal ALIX                                                            Santa Cruz                     Cat\# sc53538 RRID:AB_673821

  Rabbit monoclonal FLOTILLIN-1                                                    Abcam                          Cat\# ab133497 RRID:AB_11156367

  Mouse monoclonal GAPDH                                                           Millipore Sigma                Cat\#: CB1001 RRID:AB_2107426

  Rabbit polyclonal GFP Tag                                                        Thermo Fisher                  Cat\# A-11122; RRID:AB_221569

  Rabbit polyclonal Ki67                                                           Abcam                          Cat\# ab15580; RRID:AB_443209

  ECL Anti-rabbit IgG                                                              Sigma                          Cat\# GENA934--1 ML RRID:AB_2722659

  ECL Anti-mouse IgG                                                               Thermo Fisher                  Cat\# GENA931--1 ML

  goat-anti-rat Alexa Fluor 647                                                    Abcam                          Cat\# ab150155

  anti-CD45-PE-Cy7                                                                 BioLegend                      Cat\# 103113, clone 30-F11 RRID:AB_312978

  anti-CD45-PE                                                                     BioLegend                      Cat\# 103105, clone 30-F11 RRID:AB_312970

  anti-CD11b-Alexa Fluor 647                                                       BioLegend                      Cat\# 101220, clone M1/70; RRID:AB_493546

  anti-CD11b-PE                                                                    BioLegend                      Cat\# 101207, clone M1/70; RRID:AB_312790

  anti-CD11b-PE-Cy7                                                                BioLegend                      Cat\# 101215, clone M1/70; RRID:AB_312798

  anti-GFP-Alexa Fluor 647                                                         BioLegend                      Cat\# 338005, clone FM264G RRID:AB_1279413

  anti-GFAP-Alexa Fluor 488                                                        Thermo Fisher                  Cat\# 53--9892--80, clone GA5\
                                                                                                                  RRID:AB_10597754

  TruStain fcX                                                                     BioLegend                      Cat\# 101320, clone 93; RRID:AB_1574975

                                                                                                                  

  Virus Strains                                                                                                   

                                                                                                                  

  VSV-G Pseudotyped Lentivirus                                                     [@R75]                         Breakefield lab

                                                                                                                  

  Chemicals, Peptides, and Recombinant Proteins                                                                   

                                                                                                                  

  Dulbecco's modified Eagle's medium (DMEM)                                        Corning                        Cat\# 10--013-CV

  Roswell Park Memorial Institute (RPMI) 1640 with L-glutamine (no phenol red)     Fisher Scientific              Cat\# 11835030

  Fetal bovine serum (FBS)                                                         Gemini Bioproducts             Cat\# 900--208 Lot\# A78E00G

  Penicillin (100 units/ml) and Streptomycin (100 μg/ml) (P/S)                     Corning                        Cat\# 30--002-CI

  OptiMEM                                                                          GIBCO                          Cat\# 31985--062

  0.05% Trypsin/0.53mM EDTA in HBSS w/o calcium, magnesium or sodium bicarbonate   Corning                        Cat\# MT25052CI

  Trypsin-EDTA (0.25%), phenol red                                                 Fisher Scientific              Cat\# 25200056

  DharmaFECT 1 Transfection Reagent                                                Dharmacon                      Cat\# T-2001--01

  M-CSF recombinant mouse protein                                                  Thermo Fisher                  Cat. \# PMC2044

  cOmplete, Mini, EDTA-free protease inhibitor cocktail                            Sigma-Aldrich                  Cat\# 4693159001

  Phosphate buffered saline (PBS) 10X                                              Boston Bioproducts             Cat\# BM-220

  Ketamine                                                                         Bioniche Pharma                Cat\# NPC 67457--001--10

  Xylazine                                                                         Santa Cruz                     Cat\# sc-362950Rx

  PFA 32%                                                                          Electron Microscopy Sciences   Cat\# 100496--496

  poly-D-lysine                                                                    Sigma-Aldrich                  Cat\# P7405--5MG

  ProLong® diamond antifade mountant                                               Thermo Fisher                  Cat\# P36965

  DAPI                                                                             Thermo Fisher                  Cat\# D1306

  RBC lysis buffer                                                                 Boston BioProducts             Cat\# IBB-198

  DPBS without Mg^2+^ and Ca^2+^                                                   Corning                        Cat\# 21--031-CV

  2-mercaptoethanol                                                                Sigma Aldrich                  Cat\# 133051

  ERCC RNA Spike-In Mix                                                            Life Technologies              Cat\# 4456740

  Agencourt AMPure XP beads                                                        Beckman Coulter                Cat\# A63880

  OptiPrep Density Gradient Medium                                                 Sigma Aldrich                  Cat\# D1556

  VECTASHIELD® Antifade Mounting Medium                                            Vector Labs                    Cat\# H-1000

                                                                                                                  

  Critical Commercial Assays                                                                                      

                                                                                                                  

  RNeasy Plus Micro Kit (50)                                                       QIAGEN                         Cat\# 74034

  SMARTer Ultra Low Input RNA Kit for Sequencing -- v3                             Clontech                       Cat\# 634848, 634849, 634850, 634851, 634852 & 634853

  Nextera® XT DNA Library Preparation kit                                          Illumina                       Cat\# FC-131--1096

  SYBR® FAST Universal qPCR Kit                                                    KAPA Biosystems                Cat\# KK4600

  NextSeq 500/550 High Output v2 kit                                               Illumina                       Cat\# FC-404--2002

  1% PhiX Sequencing Control V3                                                    Illumina                       Cat\# FC-110--3001

  Neural Tissue Dissociation Kit (P)                                               Miltenyi Biotec                Cat\# 130--092--628

  BD Cytofix/Cytoperm                                                              BD Biosciences                 Cat\# 554714

  SuperScript VILO cDNA Synthesis Kit                                              Invitrogen                     Cat\# 11754050

  Pierce BCA Protein Assay Kit                                                     Thermo Fisher                  Cat\# 23225

  SuperSignal West Pico PLUS Chemiluminescent Substrate                            Thermo Fisher                  Cat\# 34580

  ddPCR Supermix for Probes (No dUTP)                                              Bio-Rad                        Cat\# 1863024

  Droplet Generation Oil for Probes                                                Bio-Rad                        Cat\# 1863005

  DG8 Gaskets for QX200/QX100 Droplet Generator                                    Bio-Rad                        Cat\# 1863009

  DG8 Cartridges for QX200/QX100 Droplet Generator                                 Bio-Rad                        Cat\# 1864008

                                                                                                                  

  Deposited Data                                                                                                  

                                                                                                                  

  RNA seq raw data (FastQ files)                                                   This paper                     GSE12607

  RNA seq processed data                                                           This paper                     GSE12607

  R script git repository                                                          This paper                     <https://github.com/slnmaas/miR21-Project>

                                                                                                                  

  Experimental Models: Cell Lines                                                                                 

                                                                                                                  

  GL261                                                                            NCI Tumor Repository           <https://dtp.cancer.gov/repositories/>

                                                                                                                  

  Experimental Models: Organisms/Strains                                                                          

                                                                                                                  

  B6;129S6-MiR-21atm1Yoli/J (miR-21-null)                                          The Jackson Laboratory         Kind gift from Dr. Anna Krichevsky

                                                                                                                  

  Oligonucleotides                                                                                                

                                                                                                                  

  Oligonucleotides for qRT-PCR                                                     This paper                     [Table S2](#SD1){ref-type="supplementary-material"}

  PrimePCR ddPCR Expression Probe Assay: Actb, Mouse                               Bio-Rad                        Unique Assay ID: dMmuCPE5195285

  PrimePCR ddPCR Expression Probe Assay: Pdcd4, Mouse                              Bio-Rad                        Unique Assay ID: dMmuCPE5113532

  PrimePCR ddPCR Expression Probe Assay: Btg2, Mouse                               Bio-Rad                        Unique Assay ID: qMmuCIP0029872

  SMARTpool: ON-TARGETplus Btg2 siRNA                                              Dharmacon                      Cat\# L-043138--01--0005

  ON-TARGETplus Non-targeting Pool                                                 Dharmacon                      Cat\# D-001810--10--05

  miRIDIAN microRNA mmu-miR-21a-5p mimic                                           Dharmacon                      Cat\# C-310515--05--0005

  miRIDIAN microRNA Mimic Negative Control \#1                                     Dharmacon                      Cat\# CN-001000--01--05

                                                                                                                  

  Recombinant DNA                                                                                                 

                                                                                                                  

  CSCW2.palmGFP                                                                    [@R41]; [@R57]                 Breakefield lab

  pHIV-H2BmRFP                                                                     [@R98]                         Kind gift of Dr. Thorsten Mempel

                                                                                                                  

  Software and Algorithms                                                                                         

                                                                                                                  

  Zen Pro 2012                                                                     ZEISS                          <https://www.zeiss.com/microscopy/us/products/microscope-software/zen.html>

  ImageJ 1.49v                                                                     NIH                            <https://imagej-nih-gov.ezp-prod1.hul.harvard.edu/ij/>

  STAR v2.4.0h                                                                     [@R18]                         <https://github.com/alexdobin/STAR>

  MarkDuplicates tool in picard-tools-1.8.4                                        Broad Institute                <http://broadinstitute.github.io/picard/>

  Gencode GRCm38.p3 GTF annotations                                                Trust Sanger Institute         <https://www.gencodegenes.org/mouse_releases/3.html>

  R (version 3.2.3)                                                                The R Foundation               <https://www.r-project.org/>

  R Studio                                                                         The R Foundation               <https://www.rstudio.com/>

  DESeq2 (version 1.10)                                                            [@R48]                         <https://bioconductor.org/packages/release/bioc/html/DESeq2.html>

  gplots (version 2.17) heatmap.2 function                                                                        <https://cran.r-project.org/web/packages/gplots/index.html>

  UpSetR (version 1.3.3)                                                           [@R15]                         <https://cran.r-project.org/web/packages/UpSetR/index.html>

  VennDiagram (version 1.6.16)                                                     [@R11]                         <https://cran.r-project.org/web/packages/VennDiagram/index.html>

  Prism                                                                            GraphPad                       <https://www.graphpad.com/scientific-software/prism/>

  FlowJo                                                                           FlowJo                         <https://www.flowjo.com/>

                                                                                                                  

  Other                                                                                                           

                                                                                                                  

  100 μm cell strainer                                                             Thermo Fisher                  Cat\# 22363549

  70 μm cell strainer                                                              Corning                        Cat\# CLS431751

  40 μm cell strainer                                                              Corning                        Cat\# 352340

  Quick-Seal® Polypropylene Tubes                                                  Beckman Coulter                Cat\# 342414

  Thinwall Polypropylene Tubes                                                     Beckman Coulter                Cat\# 326819

  Type 70 Ti Rotor                                                                 Beckman Coulter                Cat\# 337922

  MLS-50 Swinging-Bucket Rotor                                                     Beckman Coulter                Cat\# 367280

  Optima Max-XP Ultracentrifuge                                                    Beckman Coulter                Cat\# 393315

  Optima XE Ultracentrifuge                                                        Beckman Coulter                Cat\# A94471

  GentleMacs C-tube                                                                Miltenyi Biotec                Cat\# 130--093--237

  LS Columns                                                                       Miltenyi Biotec                Cat\# 130--042--401

  MidiMACS                                                                         Miltenyi Biotec                Cat\# 130--042--301

  gentleMACS Dissociator                                                           Miltenyi Biotec                Cat\# \# 130--093--235

  BD Falcon Tube with Cell Strainer Cap                                            BD Falcon                      Cat\# 08--771--23

  BD FACSAria II SORP Cell Sorter                                                  BD Falcon                      N/A

  QuantStudio 3 PCR system                                                         Applied Biosciences            N/A

  Agilent 2100 Bioanalyzer                                                         Agilent Technologies           N/A

  Amnis ImageStream mkII Imaging Flow Cytometer                                    EMD Millipore                  N/A

  NextSeq 500 sequencer                                                            Illumina                       N/A

  Mycoplasma PCR Detection Kit                                                     ABM                            Cat\# G238
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Highlights

-   Extracellular vesicles (EVs) shed by glioma cells are taken up by microglia *in vivo*

-   miR-21 is functionally transferred from glioma to microglia through EVs *in vivo*

-   miR-21 mRNA targets in microglia are downregulated upon EV uptake

-   Microglia proliferation is increased after miR-21 target *Btg2* downregulation
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